PPARβ in macrophages and atherosclerosis

Libby, 2000, Cholesterol and atherosclerosis, Biochim. Biophys. Acta, 1529, 299, 10.1016/S1388-1981(00)00161-X Phillips, 2014, Molecular mechanisms of cellular cholesterol efflux, J. Biol. Chem., 289, 24020, 10.1074/jbc.R114.583658 Chinetti-Gbaguidi, 2015, Macrophage subsets in atherosclerosis, Nat. Rev. Cardiol., 12, 10, 10.1038/nrcardio.2014.173 Gordon, 2005, Monocyte and macrophage heterogeneity, Nat. Rev. Immunol., 5, 953, 10.1038/nri1733 Vosper, 2001, The Peroxisome Proliferator-activated Receptor promotes lipid accumulation in human macrophages, J. Biol. Chem., 276, 44258, 10.1074/jbc.M108482200 Adhikary, 2015, The transcriptional PPARbeta/delta network in human macrophages defines a unique agonist-induced activation state, Nucleic Acids Res., 43, 5033, 10.1093/nar/gkv331 Thulin, 2013, MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor delta in human monocytes during the inflammatory response, Int. J. Mol. Med., 31, 1003, 10.3892/ijmm.2013.1311 Bouhlel, 2009, Unlike PPARgamma, PPARalpha or PPARbeta/delta activation does not promote human monocyte differentiation toward alternative macrophages, Biochem. Biophys. Res. Commun., 386, 459, 10.1016/j.bbrc.2009.06.047 Kang, 2008, Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity, Cell Metab., 7, 485, 10.1016/j.cmet.2008.04.002 Rolling, 1996, IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells, FEBS Lett., 393, 53, 10.1016/0014-5793(96)00835-6 Li, 2004, Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma, J. Clin. Investig., 114, 1564, 10.1172/JCI18730 Mou, 2016, Pharmacological activation of Peroxisome Proliferator-Activated Receptor {Delta} increases sphingomyelin synthase activity in THP-1 macrophage-derived foam cell, Inflammation, 39, 1538, 10.1007/s10753-016-0389-0 Bojic, 2012, Activation of peroxisome proliferator-activated receptor delta inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein, Arterioscler. Thromb. Vasc. Biol., 32, 2919, 10.1161/ATVBAHA.112.255208 Chawla, 2003, PPARdelta is a very low-density lipoprotein sensor in macrophages, Proc. Natl. Acad. Sci. U. S. A., 100, 1268, 10.1073/pnas.0337331100 Lee, 2006, Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage, Proc. Natl. Acad. Sci. U. S. A., 103, 2434, 10.1073/pnas.0510815103 Oliver, 2001, A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, Proc. Natl. Acad. Sci. U. S. A., 5306, 10.1073/pnas.091021198 Ogata, 2009, On the mechanism for PPAR agonists to enhance ABCA1 gene expression, Atherosclerosis, 205, 413, 10.1016/j.atherosclerosis.2009.01.008 Chehaibi, 2015, PPAR-beta/delta activation promotes phospholipid transfer protein expression, Biochem. Pharmacol., 94, 101, 10.1016/j.bcp.2015.01.016 Oram, 2003, Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells, J. Biol. Chem., 278, 52379, 10.1074/jbc.M310695200 Lee, 2003, Transcriptional repression of atherogenic inflammation: modulation by PPARdelta, Science, 302, 453, 10.1126/science.1087344 Welch, 2003, PPAR{gamma} and PPAR{delta} negatively regulate specific subsets of lipopolysaccharide and IFN-{gamma} target genes in macrophages, Proc. Natl. Acad. Sci. U. S. A., 100, 6712, 10.1073/pnas.1031789100 Barish, 2008, PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis, Proc. Natl. Acad. Sci. U. S. A., 105, 4271, 10.1073/pnas.0711875105 Odegaard, 2008, Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance, Cell Metab., 7, 496, 10.1016/j.cmet.2008.04.003 Tabas, 2010, Macrophage death and defective inflammation resolution in atherosclerosis, Nat. Rev. Immunol., 10, 36, 10.1038/nri2675 Mukundan, 2009, PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance, Nat. Med., 15, 1266, 10.1038/nm.2048 Sznaidman, 2003, Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)–synthesis and biological activity, Bioorg. Med. Chem. Lett., 13, 1517, 10.1016/S0960-894X(03)00207-5 Bojic, 2014, Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice, Arterioscler. Thromb. Vasc. Biol., 34, 52, 10.1161/ATVBAHA.113.301830 Graham, 2005, The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice, Atherosclerosis, 181, 29, 10.1016/j.atherosclerosis.2004.12.028 Takata, 2008, PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis, Proc. Natl. Acad. Sci. U. S. A., 105, 4277, 10.1073/pnas.0708647105 Naya, 2016, Metabolism, 65, 16, 10.1016/j.metabol.2015.09.016 Chin, 2010, Selective peroxisome proliferator-activated receptor delta isosteric selenium agonists as potent anti-atherogenic agents in vivo, Bioorg. Med. Chem. Lett., 20, 7239, 10.1016/j.bmcl.2010.10.103 Piqueras, 2009, Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release, J. Leukoc. Biol., 86, 115, 10.1189/jlb.0508284 Li, 2016, Hematopoietic knockdown of PPARdelta reduces atherosclerosis in LDLR-/- mice, Gene Ther., 23, 78, 10.1038/gt.2015.78